WaveMan
WaveMan · Company
ADTX · Aditxt, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ADTX Aditxt (ADTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001726711
Quote by TradingView
Activist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about ADTX

Insiders, 180 days
+$23.5K net bought
2 buyers · 5 sellers · 0% of sales under a 10b5-1 plan
Activist stakes (13D), 180 days
1 filing
Largest: 10.9% of the class

Aditxt insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Aditxt, Inc. insiders bought a net $23.5K of stock across 27 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Takeover Time 2026 LLC
SELL
2026-06-25 SECtraded 2026-06-23
3,420,439
$68.4K
-50.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 4 other insiders sold within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Takeover Time 2026 LLC sold about $68.4K of ADTX on Jun 23, 2026; 4 other insiders sold within 30 days.
HRT FINANCIAL LP
SELL
2026-06-24 SECtraded 2026-06-22
5,120,480
$102.4K
-50.0%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (8 buys, 8 sales), the last on Jun 18, 2026.
  • -54.8% median (-64.9% mean) 90-day return after 8 previous buys.
  • 4 other insiders sold within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP sold about $102.4K of ADTX on Jun 22, 2026, the largest insider sale at the company since 2023; 4 other insiders sold within 30 days.
HRT FINANCIAL LP
BUY
2026-06-24 SECtraded 2026-06-18
7,340,178
$73.4K
-50.0%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (7 buys, 8 sales), the last on Jun 16, 2026.
  • -57.9% median (-67.0% mean) 90-day return after 7 previous buys.
  • The trade is 305.0% of the 2,406,438 shares held after it.
  • 1 other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP bought about $73.4K of ADTX on Jun 18, 2026; 1 other insider bought within 30 days.
DRW Securities, LLC
SELL
2026-06-18 SECtraded 2026-06-17
126,772
$1.3K
-94.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 4 other insiders sold within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DRW Securities, LLC sold about $1.3K of ADTX on Jun 17, 2026; 4 other insiders sold within 30 days.
HRT FINANCIAL LP
SELL
2026-06-18 SECtraded 2026-06-16
3,132,480
$31.3K
-94.7%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (7 buys, 7 sales), the last on Jun 15, 2026.
  • -57.9% median (-67.0% mean) 90-day return after 7 previous buys.
  • 4 other insiders sold within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP sold about $31.3K of ADTX on Jun 16, 2026; 4 other insiders sold within 30 days.
27 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 22 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$23.5K over 180 days
+$23.5K of it by a 10%+ holder
more than 69% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-97.6% year over year
below 91% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.0 days to cover · settled 2026-09-30
The situation: each line is one rule over one dataset
Takeover Time 2026 LLC disclosed a 5%+ stake (10.9%) in the last six months.
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 9 in the prior 90
Why it matters
The absence is the signal: 9 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 28Insider buying stopped: no purchases in 90 days after 9 in the prior 90
Why it matters
The absence is the signal: 9 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch ADTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-100.0%12M
-100%-67%-33%+0%2025-102025-122026-022026-042026-062026-08 2026-06-22 · HRT FINANCIAL LP sold $102.4K2026-06-12 · HRT FINANCIAL LP bought $85.1K2026-06-18 · HRT FINANCIAL LP bought $73.4K2026-06-08 · HRT FINANCIAL LP bought $71.2K2026-06-23 · Takeover Time 2026 LLC sold $68.4K2026-06-04 · HRT FINANCIAL LP bought $67.5K2026-06-05 · HRT FINANCIAL LP sold $44.1K2026-06-16 · HRT FINANCIAL LP sold $31.3K2026-06-11 · HRT FINANCIAL LP sold $28.3K2026-06-09 · HRT FINANCIAL LP sold $26.4K2026-04-21 · HRT FINANCIAL LP bought $24.1K2026-06-15 · HRT FINANCIAL LP bought $21.1K2026-06-10 · HRT FINANCIAL LP bought $14.5K2026-04-24 · HRT FINANCIAL LP sold $8.2K2026-06-09 · Gong Sandie sold $7.0K2026-04-22 · HRT FINANCIAL LP sold $3.6K2026-06-17 · DRW Securities, LLC sold $1.3K2026-04-23 · HRT FINANCIAL LP sold $1.1K2025-11-25 · Pankovcin Corinne sold $32025-12-17 · Brady Brian Michael sold $22026-06-11 · BOFA SECURITIES, INC. sold $02026-06-11 · BOFA SECURITIES, INC. bought $02026-06-11 · BOFA SECURITIES, INC. bought $02026-06-11 · BOFA SECURITIES, INC. bought $02026-06-22 · Takeover Time 2026 LLC filed a 5%+ stake (10.9%)
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ADTX: institutional holders (13F)

13F holdings, latest reported quarter
IFP Advisors, Inc
1 sh
$0

Congress trades in ADTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Takeover Time 2026 LLC
Activist 13D · 2026-06-22
10.9%

ADTX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $23.5K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ADTX financials

Revenue growth
-97.6%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$14.3K
four quarters, 2025-04-01 to 2026-03-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-3,710,735.20x
TTM operating cash flow over long-term debt only, 2021-01-25 (63 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-236.4%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-220.7%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
P/E, trailing
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Enterprise value
-$162.2K
market value at close 2026-10-26 on 2026-05-20 shares, plus long-term debt only, 2021-01-25 (63 months older than the period end), minus cash 2025-09-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$3.2K$134.0K$645.2K$933.7K
Gross profit$268-$493.5K-$111.7K$166.9K
Operating income-$19.6M-$27.9M-$26.1M-$25.5M
Net income-$43.1M-$40.4M-$32.7M-$27.6M
EPS (diluted)-1,153.83-22,147,415.22-27,038.26-595.60
Operating cash flow-$25.7M-$16.8M-$19.2M-$22.4M
Cashn/a$833.0K$97.1K$2.8M
SEC XBRL, fiscal years, as known on 2026-10-28

ADTX Stock Sonar score 5/7 axes

Find similar shapesCompare

ADTX ranks highest on insider conviction (75th percentile) and risk and compliance (39th), and lowest on financial health (1st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersRisk
Profitability
9
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-236.4% · 9 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-220.7% · 9 pct, sector of 576
Financial health
0
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-3710735.20x · 0 pct, sector of 371
Growth
9
Inputs
  • Revenue growth, YoY-97.6% · 9 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
75
Inputs
  • Net Form 4 buying (codes P and S), 180d$24K · 68 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Risk and compliance
39
Inputs
  • Short interest, % of floatno short interest or no free float on file
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+12.9% · 39 pct, sector of 511
2 not measured: Institutional and government, US patents
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ADTX filings, in plain words

Are Aditxt insiders buying or selling ADTX?

In the 180 days to 2026-10-28, Aditxt insiders were net buyers, a net $23.5K: $332.8K of purchases and $309.2K of sales reported on Form 4, by 2 buyers and 5 sellers.

Read the full summary

In the 180 days to 2026-10-28, Aditxt insiders were net buyers of ADTX, a net $23.5K across purchases and sales reported on Form 4 by 2 buyers and 5 sellers. Most of that figure, $23.5K, came from a holder of 10% or more rather than an officer or director. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 10.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies